Harvard Bioscience gets new Nasdaq bid price deadline
Harvard Bioscience, Inc. received notice from Nasdaq that it has been granted an additional 180 days, until March 30, 2026, to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share for continued listing.
Rhea-AI Filing Summary
Harvard Bioscience, Inc. received notice from Nasdaq that it has been granted an additional 180 days, until March 30, 2026, to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share for continued listing. To qualify for this second compliance period, the company applied to transfer its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, and this transfer becomes effective at the opening of business on October 3, 2025.
The company originally fell out of compliance after its closing bid price stayed below $1.00 for 30 consecutive business days. If the stock closes at or above $1.00 for at least 10 consecutive business days before March 30, 2026, Nasdaq staff will confirm that the company has regained compliance. If compliance is not restored by that date, the stock will be subject to delisting, although the rules allow the company to appeal. The company plans to monitor its share price and may consider options such as a reverse stock split to regain compliance.
Positive
- None.
Negative
- Delisting risk and listing downgrade: HBIO has transferred from the Nasdaq Global Market to the Nasdaq Capital Market and faces potential delisting if it cannot lift its share price back to the $1.00 minimum bid level by March 30, 2026.
Insights
Nasdaq grants HBIO more time but delisting risk remains.
Harvard Bioscience has secured a second 180‑day compliance period from Nasdaq, extending its deadline to restore its share price to at least $1.00 per share until March 30, 2026. The company also shifted its listing tier from the Nasdaq Global Market to the Nasdaq Capital Market, which generally has less stringent initial listing standards but similar trading mechanics.
Regaining compliance requires the stock to close at or above $1.00 for at least 10 consecutive business days. Failing that, the shares become subject to delisting, though the rules provide for an appeal to a hearings panel. The company notes it may use tools such as a reverse stock split, which can mechanically raise the share price but does not change the underlying business performance.
For investors, the key implication is binary: either the company restores compliance by March 30, 2026 or it faces a delisting process that could shift trading to a less liquid venue. The filing emphasizes that there is no assurance the company will meet the minimum bid requirement or remain in full compliance with all Nasdaq rules.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Harvard Bioscience (HBIO) receive a Nasdaq notice?
What additional time has Harvard Bioscience (HBIO) been given to regain Nasdaq bid price compliance?
What change is Harvard Bioscience (HBIO) making to its Nasdaq listing?
How can Harvard Bioscience (HBIO) regain compliance with Nasdaq’s minimum bid price rule?
What happens if Harvard Bioscience (HBIO) does not meet the $1.00 bid price by March 30, 2026?
What actions might Harvard Bioscience (HBIO) take to address its Nasdaq bid price deficiency?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
______________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On October 2, 2025, Harvard Bioscience, Inc., (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been granted an additional 180 days, or until March 30, 2026 (the “Second Compliance Period”), to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period. In order to be eligible to receive the Second Compliance Period, the Company applied to have its common stock (the “Common Stock”) transferred from the Nasdaq Global Market to the Nasdaq Capital Market. In connection with the grant of the Second Compliance Period, the application was approved and the Common Stock will move to the Nasdaq Capital Market effective at the opening of business on October 3, 2025.
As previously disclosed by the Company in a Current Report on Form 8-K filed on April 10, 2025, the Company received a notification letter from the Staff notifying the Company that, because the closing bid price for the Common Stock listed on the Nasdaq Global Market had been below $1.00 for 30 consecutive business days, the Company no longer met the Minimum Bid Price Requirement.
If at any time before March 30, 2026, the bid price of the Common Stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance, subject to the Staff’s discretion to extend the minimum bid price compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the Second Compliance Period, the Common Stock will become subject to delisting. In the event that the Company receives notice that the Common Stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel.
The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and the Company’s Common Stock will continue to be listed and traded under the symbol “HBIO.”
The Company intends to continue to monitor the closing bid price of the Common Stock between now and March 30, 2026, and will consider available options to regain compliance with the Minimum Bid Price Requirement, including effecting a reverse stock split, if necessary. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HARVARD BIOSCIENCE, INC. | |||
| Date: October 3, 2025 | By: | /s/ Mark Frost | |
| Mark Frost | |||
| Interim Chief Financial Officer | |||